Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR

To understand the profile of best responders (complete response or better [≥CR]) to carfilzomib, we described the characteristics, progression-free survival (PFS), overall survival (OS) data, and the safety of patients who achieved ≥CR to carfilzomib-based treatment in ASPIRE and ENDEAVOR. In post h...

Descripción completa

Detalles Bibliográficos
Autores principales: Weisel, Katja, Mateos, Maria-Victoria, Gay, Francesca, Delforge, Michel, Cook, Gordon, Szabo, Zsolt, Desgraz, Renaud, DeCosta, Lucy, Moreau, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179852/
https://www.ncbi.nlm.nih.gov/pubmed/33067574
http://dx.doi.org/10.1038/s41375-020-01049-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179852/
https://www.ncbi.nlm.nih.gov/pubmed/33067574
http://dx.doi.org/10.1038/s41375-020-01049-5

Ejemplares similares